ERBB2 and gastric cancer: HER2+ subgroup also had significantly higher TMB level and MATH score but comparable PD‐L1 expression level and MSI status when compared with HER2− subgroup, indicating that GC patients with HER2 amplifications may be one of the potential benefit populations.